Screening and study enrolment in the randomized evaluation of normal vs. augmented level (RENAL) replacement therapy trial

Blood Purification

Volumn 27, Issue 2, 2009, Pages 199-205

  Bellomo, Rinaldo ^a   Cass, Alan ^b   Cole, Louise ^b   Finfer, Simon ^b   Gallagher, Martin ^b   Goldsmith, Donna ^b   Myburgh, John ^b   Norton, Robyn ^b   Scheinkestel, Carlos ^b   Bhonagiri, Ashoke Banarjee Deepak ^b   Blythe, David ^b   Botha, John ^b   Cade, John ^b   Dobb, Geoff ^b   Eddington, John ^b   Flabouris, Arthas ^b   French, Craig ^b   Garrett, Peter ^b   Henderson, Seton ^b   Ihle, Benno ^b   Joyce, Chris ^b   Kalkoff, Michael ^b   Lipman, Jeff ^b   McArthur, Colin ^b   McGinness, Shay ^b   Milliss, David ^b   Mitchell, Imogen ^b   Morgan, John ^b   Nair, Priya ^b   Orford, Neil ^b   Raza, Asif ^b   Shehabi, Yahya ^b   Tobin, Antony ^b   Totaro, Richard ^b   Turner, Andrew ^b   Wright, Christopher ^b   more..

^a AUSTIN HEALTH   (Australia)

^b NONE

Author keywords

CONSORT statement; Continuous renal replacement therapy; Renal replacement therapy; RENAL Trial; VA NIH ATN study

Indexed keywords

ARTICLE; BODY WEIGHT; CLINICAL STUDY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; HEMODIALYSIS; HUMAN; INFORMATION PROCESSING; INFORMED CONSENT; KIDNEY FAILURE; KIDNEY INJURY; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; METHODOLOGY; PATIENT SELECTION; PERSONNEL; PRIORITY JOURNAL; RANDOMIZATION; RENAL REPLACEMENT THERAPY; SCREENING; VALIDATION STUDY;

HUMANS; INFORMED CONSENT; KIDNEY FAILURE, CHRONIC; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL REPLACEMENT THERAPY; RESEARCH SUBJECTS;

EID: 61649119640     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000195091     Document Type: Article

References (16)

1. Altman DG, Schulz KF, Moher D, et al: The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-694.
2. Shapiro SH, Weijer C, Freedman B: Reporting the study population of clinical trials: clear transmission or static on the line? J Clin Epidemiol 2000;53:973-979.
3. Gandhi M, Ameli N, Bacchetti P, et al: Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS 2005;19:1885-1896.
4. Moher D, Schulz KF, Altman DG, Consort G: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;134:657-662.
5. Crowley ST, Chertow GM, Vitale J, et al: Lessons for successful study enrolment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clin J Am Soc Nephrol 2008;3:955-961.
6. The RENAL Investigators: Renal replacement therapy for acute kidney injury in Australian and New Zealand intensive care units: a practice survey. Crit Care Resusc 2008;10:225-230.
7. The RENAL Investigators: Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high-dose versus standard-dose hemofiltration in acute renal failure. Blood Purif 2008;26:407-416.
8. Uchino S, Morimatsu H, Bellomo R, et al: End-stage renal failure patients requiring renal replacement therapy in the intensive care unit: incidence, clinical features, and outcome. Blood Purif 2003;21:170-175.
9. Bell M, Granath F, Schoen S, et al: End-stage renal disease patients on renal replacement therapy in the intensive care unit: short- and medium-term outcome. Crit Care Med 2008;36:2773-2778.
10. The Canadian Critical Care Trials Group: A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006;355:2619-2630.
11. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-247.
12. The NHLBI ARDS Clinical Trials Network: Comparison of two fluid management strategies in acute lung injury. N Engl J Med 2006;354:1-12.
13. The NHLBI ARDS Clinical Trials Network: Efficacy and safety of corticosteroids in persistent acute respiratory distress syndrome. N Engl J Med 2006;354:1671-1684.
14. Bernard GR, Vincent J-L, Laterre P-F, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
15. Sprung CL, Annane D, Keh D, et al: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-124.
16. Brunkhorst FM, Engel C, Bloos F, et al: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-139.